Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

IMPACT IMproving the outcome of Peritoneal and Pleural metastases using Aerosolized ChemoTherapy

Coordinator
Universiteit Gent, Belgium
Runs
1 July 2026 to 30 June 2032
Status
Running
EU funding
€10.0m
Total cost
€10.0m
Partners
13 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101288858

What the project is doing

In the project's own words, from its summary on CORDIS.

Improved therapy of peritoneal metastases (PM) and malignant pleural effusion (MPE) is an important clinical need. Recently, intracavitary aerosolized drug delivery (ADD) has been introduced in the treatment of PM and MPE. This innovative, EU developed therapy involves nebulization of chemotherapy during either laparoscopy (pressurized intraperitoneal aerosolized chemotherapy, PIPAC) or thoracoscopy (pressurized intraperitoneal aerosolized chemotherapy, PIPAC).

Also, preliminary data suggest that ADD may be optimized by using electrostatic precipitation (ESP). As yet, however, no randomized trials have tested the efficacy of PIPAC or PITAC. The IMPACT project aims to establish ADD as a novel standard of care in patients with PM and MPE. First, a comprehensive assessment of patient needs and expectations will be performed, supported by experts in participatory research methods.

Based on the input of multiple stakeholders including patients, methodologists, and health care professionals, three randomized clinical trials will be designed in PM from colorectal and gastric cancer, and in MPE. These trials will be run in more than 30 clinical sites in 7 EU countries, and will include >500 patients. In a subgroup of patients, the effects of ESP on drug distribution and tumor tissue penetration will be studied.

In addition to clinical and patient related outcomes, health technological assessment will be performed to establish cost effectiveness and value in diverse EU health care systems. To reach all relevant stakeholders, a broad range of communication, exploitation, and dissemination tasks will be performed in order to maximize the visibility and impact of the project results. In parallel, a modular implementation strategy will be deployed to maximize clinical adoption of this innovative treatment strategy and ensure acceptability, usability, and scalability in diverse health care settings.

This action is part of the Cancer Mission cluster of projects on “Diagnosis and Treatment-Innovative Surgery

Topics

Who is involved

OrganisationCityCountryRole
Universiteit GentGentBelgiumCoordinator
Digestive Cancers Europe DiceBruxelles / BrusselBelgiumParticipant
European Cancer OrganisationBruxelles / BrusselBelgiumParticipant
European Society of Surgical OncologyWoluwe-Saint-LambertBelgiumParticipant
Capnopharm GmbHTubingenGermanyParticipant
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyParticipant
Region SyddanmarkVejleDenmarkParticipant
Syddansk UniversitetOdense MDenmarkParticipant
Consorci Sanitari IntegralL'Hospitalet De LlobregatSpainParticipant
Institut Regional Du Cancer De MontpellierMontpellier Cedex 5FranceParticipant
Fondazione Policlinico Universitario Agostino Gemelli IrccsRomaItalyParticipant
Universita Commerciale Luigi BocconiMilanoItalyParticipant
Alesi Surgical LimitedCardiffUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI